ReviewTargeted oncology2010
Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives.
Review in Targeted oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma.Acta neuropathologica communications · 2018Trial
- Glioma‑associated microglia and macrophages as a potential target for mTOR inhibition in glioblastoma.Molecular medicine reports · 2025Article
- Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.Journal of neuro-oncology · 2022Article
- Activation of Epidermal Growth Factor Receptor Sensitizes Glioblastoma Cells to Hypoxia-Induced Cell Death.Cancers · 2020Article
- Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.Journal of clinical medicine · 2019Article
- Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment.International journal of molecular sciences · 2019Article
- EGFR and mTOR as therapeutic targets in glioblastoma.Oncotarget · 2019Article
- The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma.British journal of cancer · 2019Article
- Determination of the relationship between doxorubicin resistance and Wnt signaling pathway in HeLa and K562 cell lines.EXCLI journal · 2018Article
- Glial progenitors as targets for transformation in glioma.Advances in cancer research · 2014Review
- EZH2 silencing with RNA interference induces G2/M arrest in human lung cancer cells in vitro.BioMed research international · 2014Article
- Low Concentration Microenvironments Enhance the Migration of Neonatal Cells of Glial Lineage.Cellular and molecular bioengineering · 2012Article
- The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas.Neurology research international · 2012Article
- Transforming growth factor α transforms astrocytes to a growth-supportive phenotype after spinal cord injury.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2011Article
- EGFR expression stratifies oligodendroglioma behavior.The American journal of pathology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in the understanding of the molecular biology of glioblastomas (GB), these neoplasms still are incurable with conventional therapies. Current efforts therefore focus on the development of new molecular approaches that exploit the genetic aberrations of cancer cells. Based on their frequent activation or mutation in human GB and their paramount role for the maintenance of the neoplastic phenotype, both the epidermal growth factor receptor (EGFR) and the mammalian target of rapamycin (mTOR) are plausible targets for molecular therapies. However, clinical trials with drugs targeting EGFR or mTOR, so far, have produced largely disappointing results. In this article, we review strategies targeting EGFR and mTOR as therapies for malignant glioma. Recent advances in the understanding of the complex signaling network involved are highlighted and the results of clinical trials are summarized. Mechanisms of resistance are explored, and potential future directions as well as trends in preclinical and clinical development are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.